Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Exp Neurol. 2008 Mar 10;211(2):529–538. doi: 10.1016/j.expneurol.2008.02.023

Fig. 4.

Fig. 4

VP inhibits caspase-3 activation through V1 VP receptors. H32 hypothalamic cells were incubated in serum-free conditions for 6h with or without VP (10 nM). Aliquots of the selective V1a VP receptor antagonist SR49059 or the V1b VP receptor antagonist SSR149415 or vehicle were added 30 min before VP treatment. Caspase-3 activity was determined. The bars represent the mean ± S.E.M of three experiments conducted in duplicate. * p< 0.05, compared to serum-free group; # p< 0.05 compared to serum-free plus VP group.